AcuraStem is a patient-based biotechnology company that is revolutionizing the way treatments are developed for neurodegenerative diseases. Based in Monrovia, California, AcuraStem is at the forefront of drug discovery, using their proprietary iNeuroRx® technology platform to develop novel and effective treatments.

The company’s groundbreaking approach involves creating individual patient models that accurately recapitulate neurodegenerative disease processes. This patient-based approach leads to more effective treatments that can work broadly for patients, not limited to rare, genetically defined subtypes.

AcuraStem’s therapeutic pipeline is robust and diverse. They have utilized their technology to advance highly promising therapeutic candidates for the treatment of ALS and FTD. They are confident these treatments will be effective for diverse forms of disease, not limited to rare, genetically defined subsets.